Tris Pharma Creates Onyda XR: The First Liquid Non-stimulant Medication For ADHD.

1. Onyda XR is the only non-stimulant medication with nighttime dosing indications.
2. Onyda XR can be added as an adjunct therapy to a psychostimulant when monotherapy with a psychostimulant is ineffective.

The Latest
Created by Tris Pharma, there is now the first and only liquid non-stimulant ADHD medication approved in the United States and the only ADHD medication approved for nighttime dosing. In a fixed-dose clinical trial, improvements in ADHD symptoms based on the ADHD rating Scale-IV-Parent Version were statistically superior in those treated with Onyda XR compared with placebo-treated patients. By providing a liquid formulation and a different dosing schedule, the expanded ADHD therapeutic options can now cater to individual needs, especially for those who have had an inadequate response or difficulty using a psychostimulant.

Physician’s Perspective
Attention-Deficit Hyperactivity Disorder (ADHD) is defined by the Centre for Addiction and Mental Health as a disorder that affects attention span, concentration, and impulsivity. There is no consensus about what precisely causes ADHD, but it is suspected to be the result of a combination of genetic and environmental factors. In a 2nd clinical trial, Onyda XR used as an adjunct to a psychostimulant showed a statistically significant improvement in ADHD symptoms compared to treatment with a psychostimulant alone. For physicians, this would mean if a patient has not seen improvement in symptoms using a psychostimulant, Onyda XR can be added as additional therapy. The safety of Onyda XR is based on clinical trials in pediatric patients 6 years and older. The most common side effects of Onyda XR include drowsiness, fatigue, irritability, nightmares, and dry mouth.

Molecular Target of Therapy
A possible theory for the cause of ADHD is the dysregulation of central noradrenergic networks. The activation of noradrenergic systems significantly influences attention performance, notably sustaining arousal—a cognitive function notably impaired in individuals with ADHD. Onyda XR is a centrally acting alpha2-adrenergic agonist which attempts to correct the dysregulation of noradrenergic networks. The exact mechanism of action by Onyda XR on ADHD is still unknown.
Company History
Tris Pharma is a privately owned, 24-year-old manufacturer that is focused on solving therapeutic challenges in ADHD, pain, addiction, and other diseases of the central nervous system. Using the company’s LiquiXR drug delivery technology, Tris can have immediate-release products transformed into those with extended-release characteristics. Therapies currently in the pipeline at Tris include treatments for opioid addiction and chronic neuropathic pain.

Further reading: https://www.drugs.com/onyda-xr.html

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.